Resomelagon is under clinical development by SynAct Pharma and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

EOM-613 is under clinical development by EOM Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Sepsis, a severe and often fatal complication of infection, is a leading cause of both acute lung injury (ALI) and acute ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

This is a retrospective study of the history, roentgenology and autopsy pathology when appropriate of all infants with severe respiratory-distress syndrome who required twenty-four hours or more ...

As for testing, the girl's first swab at BC Children's was positive for influenza A but negative for H1 or H3 disease.

The hospitalized teen was also given three antiviral treatments, underscoring how severe H5N1 infection can be ...

Veru ( ) just unveiled an update. Veru Inc. announced the sale of its FC2 Female Condom business to Clear Future, Inc. for $18 million. This divestment allows Veru to focus on its ...

The association between age and 90-day mortality in acute respiratory distress syndrome was nonlinear. The risk for death stayed elevated after a patient turned 65 years old but rose in a slower ...

First, the baby's mother had spotting in the first trimester. Later, she noticed her cervix had started to open. Her baby boy ...

About Veru Inc. Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic diseases, oncology, and ARDS. The Company's drug ...